Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cell-based Immunotherapy for Triple Negative Breast Cancer Stages II and III
2023-506019-16-01Phase 2Withdrawn
- Sponsor
- Celica Biomedical
- Start
- Jul 2024
- Countries
- 1
01
Overview
Phase 2 trial of aHyC in triple-negative breast cancer (TNBC), sponsored by Celica Biomedical. Planned start Jul 2024; status: withdrawn.
02
Drugs
aHyC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-506019-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506019-16-01.